lncRNA Biomarkers of Glioblastoma Multiforme

Markéta Pokorná,Marie Černá,Stergios Boussios,Saak V. Ovsepian,Valerie Bríd O'Leary

DOI: https://doi.org/10.3390/biomedicines12050932

IF: 4.757

2024-04-24

Biomedicines

Abstract:Long noncoding RNAs (lncRNAs) are RNA molecules of 200 nucleotides or more in length that are not translated into proteins. Their expression is tissue-specific, with the vast majority involved in the regulation of cellular processes and functions. Many human diseases, including cancer, have been shown to be associated with deregulated lncRNAs, rendering them potential therapeutic targets and biomarkers for differential diagnosis. The expression of lncRNAs in the nervous system varies in different cell types, implicated in mechanisms of neurons and glia, with effects on the development and functioning of the brain. Reports have also shown a link between changes in lncRNA molecules and the etiopathogenesis of brain neoplasia, including glioblastoma multiforme (GBM). GBM is an aggressive variant of brain cancer with an unfavourable prognosis and a median survival of 14–16 months. It is considered a brain-specific disease with the highly invasive malignant cells spreading throughout the neural tissue, impeding the complete resection, and leading to post-surgery recurrences, which are the prime cause of mortality. The early diagnosis of GBM could improve the treatment and extend survival, with the lncRNA profiling of biological fluids promising the detection of neoplastic changes at their initial stages and more effective therapeutic interventions. This review presents a systematic overview of GBM-associated deregulation of lncRNAs with a focus on lncRNA fingerprints in patients' blood.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of long non - coding RNA (lncRNA) in Glioblastoma Multiforme (GBM) and its potential as a biomarker. GBM is a highly malignant brain tumor, characterized by strong invasiveness and poor prognosis, and the average survival time of patients is only 14 - 16 months. Due to the high heterogeneity and invasiveness of GBM, it is very difficult to completely remove the tumor, and the high postoperative recurrence rate is the main cause of patient death.

The author points out that lncRNA has specific expression in different tissues and cell types and is related to a variety of physiological processes and disease states. Especially in the nervous system, the change in lncRNA expression is closely related to the occurrence and development of brain tumors. Therefore, by studying the expression pattern of lncRNA in GBM, new clues can be provided for early diagnosis, treatment intervention and prognosis evaluation.

Specifically, this paper aims to systematically review the expression changes of lncRNA related to GBM, especially focusing on the lncRNA fingerprint in the blood of patients. Through these studies, the author hopes to discover new biomarkers that can be used for early detection and effective treatment of GBM.